A defucosylated anti-PD-L1 monoclonal antibody 13-mG_2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.

ABSTRACT: Programmed cell death ligand-1 (PD-L1) is a type I transmembrane glycoprotein expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. A strong correlation has been reported between PD-L1 expression in tumor cells and negative prognosis in cancer patients. Previously, we established an anti-PD-L1 monoclonal antibody (mAb), L₁Mab-13 (IgG₁, kappa), by immunizing mice with PD-L1-overexpressing CHO-K1 cells. L₁Mab-13 specifically reacts with endogenous PD-L1 in lung cancer cell lines in flow cytometry and Western blot applications, and stains a plasma membrane-like pattern in lung cancer tissues via immunohistochemical analysis. In this study, we investigated whether L₁Mab-13 reacts with oral cancer cel

SUBMITTER: Takei J 

PROVIDER: S-EPMC7475192 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature